INDICATIONS AND USAGE Isosorbide Mononitrate Extended-Release Tablets, USP are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode.
West-Ward Pharmaceutical Corp
HOW SUPPLIED Isosorbide Mononitrate Extended-Release Tablets, 30 mg: film-coated Light Rose, oval Tablets; debossed "WW" on one scored side and "30" on the other scored side. Bottles of 100 tablets. Bottles of 500 tablets. Bottles of 1000 tablets. Isosorbide Mononitrate Extended-Release Tablets, 60 mg: film-coated Light yellow, oval Tablets; debossed "WW" on one scored side and "60" on the other scored side. Bottles of 100 tablets. Bottles of 500 tablets. Bottles of 1000 tablets. Store at 20 to 25Â°C (68 to 77Â°F) [See USP Controlled Room Temperature]. Protect from light and moisture. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Manufactured by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724 Revised May 2016
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site